tag:blogger.com,1999:blog-90299132024-02-19T02:08:26.514-05:00OVARIAN CANCER and USAn ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
<blockquote>“Not everything that can be counted counts and not everything that counts can be counted.”</blockquote>
Albert Einstein
OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.comBlogger19040110tag:blogger.com,1999:blog-9029913.post-23715055661362808892018-02-13T21:43:00.002-05:002018-02-13T21:43:55.952-05:00open access Feb 13, 2018: The Yet Unrealized Promise of Ovarian Cancer Screening<h1 class="meta-article-title ">
<span style="font-size: small;"><a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2672788?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaoncology&utm_content=olf&utm_term=021318" target="_blank">The Yet Unrealized Promise of Ovarian Cancer Screening</a></span></h1>
<h1 class="meta-article-title ">
<span style="font-size: small;"> </span></h1>
<div class="h3 cb section-type-references ">
<div class="heading-text thm-col">
<h2>
<b>References
</b></h2>
</div>
</div>
<div class="references">
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r1">1.</a><br />
<div class="reference-content">
US
Preventive Services Task Force. Screening for ovarian cancer: US
Preventive Services Task Force recommendation statement [published
February 13, 2018]. <i> JAMA</i>. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.21926">10.1001/jama.2017.21926</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Screening%20for%20ovarian%20cancer%3A%20US%20Preventive%20Services%20Task%20Force%20recommendation%20statement&publication_year=&journal=JAMA&volume=&pages=" target="_blank">Google Scholar</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r2">2.</a><br />
<div class="reference-content">
Henderson
JT, Webber
EM, Sawaya
GF. Screening for ovarian cancer: updated evidence report and
systematic review for the US Preventive Services Task Force [published
February 13, 2018]. <i> JAMA</i>. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.2017.21421">10.1001/jama.2017.21421</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Screening%20for%20ovarian%20cancer%3A%20updated%20evidence%20report%20and%20systematic%20review%20for%20the%20US%20Preventive%20Services%20Task%20Force&author=JT%20Henderson&author=EM%20Webber&author=GF%20Sawaya&publication_year=&journal=JAMA&volume=&pages=" target="_blank">Google Scholar</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r3">3.</a><br />
<div class="reference-content">
Jacobs
IJ, Menon
U, Ryan
A,
et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i> Lancet</i>. 2016;387(10022):945-956.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/26707054" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Ovarian%20cancer%20screening%20and%20mortality%20in%20the%20UK%20Collaborative%20Trial%20of%20Ovarian%20Cancer%20Screening%20(UKCTOCS).&author=IJ%20Jacobs&author=U%20Menon&author=A%20Ryan&publication_year=2016&journal=Lancet&volume=387&pages=945-956" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1016/S0140-6736(15)01224-6" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r4">4.</a><br />
<div class="reference-content">
Buys
SS, Partridge
E, Black
A,
et al; PLCO Project Team. Effect of screening on ovarian cancer
mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer
screening randomized controlled trial. <i> JAMA</i>. 2011;305(22):2295-2303.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/21642681" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20screening%20on%20ovarian%20cancer%20mortality%3A%20the%20Prostate%2C%20Lung%2C%20Colorectal%20and%20Ovarian%20(PLCO)%20cancer%20screening%20randomized%20controlled%20trial.&author=SS%20Buys&author=E%20Partridge&author=A%20Black&publication_year=2011&journal=JAMA&volume=305&pages=2295-2303" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1001/jama.2011.766" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r5">5.</a><br />
<div class="reference-content">
Jacobs
IJ, Skates
SJ, MacDonald
N,
et al. Screening for ovarian cancer: a pilot randomised controlled trial. <i> Lancet</i>. 1999;353(9160):1207-1210.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/10217079" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Screening%20for%20ovarian%20cancer%3A%20a%20pilot%20randomised%20controlled%20trial.&author=IJ%20Jacobs&author=SJ%20Skates&author=N%20MacDonald&publication_year=1999&journal=Lancet&volume=353&pages=1207-1210" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1016/S0140-6736(98)10261-1" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r6">6.</a><br />
<div class="reference-content">
Barrett
J, Jenkins
V, Farewell
V,
et al; UKCTOCS trialists. Psychological morbidity associated with
ovarian cancer screening: results from more than 23,000 women in the
randomised trial of ovarian cancer screening (UKCTOCS). <i> BJOG</i>. 2014;121(9):1071-1079.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/24865441" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Psychological%20morbidity%20associated%20with%20ovarian%20cancer%20screening%3A%20results%20from%20more%20than%2023%2C000%20women%20in%20the%20randomised%20trial%20of%20ovarian%20cancer%20screening%20(UKCTOCS).&author=J%20Barrett&author=V%20Jenkins&author=V%20Farewell&publication_year=2014&journal=BJOG&volume=121&pages=1071-1079" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1111/bjo.2014.121.issue-9" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r7">7.</a><br />
<div class="reference-content">
American
College of Obstetricians and Gynecologists (ACOG) Committee on
Gynecologic Practice; Society of Gynecologic Oncology. ACOG Committee
opinion No. 716, September 2017. <a href="https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Role-of-the-Obstetrician-Gynecologist-in-the-Early-Detection-of-Epithelial-Ovarian-Cancer-in">https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Role-of-the-Obstetrician-Gynecologist-in-the-Early-Detection-of-Epithelial-Ovarian-Cancer-in</a>. Accessed January 22, 2018.</div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r8">8.</a><br />
<div class="reference-content">
Marchetti
C, De Felice
F, Palaia
I,
et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on
impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA
2 mutation carriers. <i> BMC Womens Health</i>. 2014;14:150.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/25494812" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Risk-reducing%20salpingo-oophorectomy%3A%20a%20meta-analysis%20on%20impact%20on%20ovarian%20cancer%20risk%20and%20all-cause%20mortality%20in%20BRCA%201%20and%20BRCA%202%20mutation%20carriers.&author=C%20Marchetti&author=F%20De%20Felice&author=I%20Palaia&publication_year=2014&journal=BMC%20Womens%20Health&volume=14&pages=150" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1186/s12905-014-0150-5" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r9">9.</a><br />
<div class="reference-content">
Rosenthal
AN, Fraser
LSM, Philpott
S,
et al; United Kingdom Familial Ovarian Cancer Screening Study
collaborators. Evidence of stage shift in women diagnosed with ovarian
cancer during phase II of the UK Familial Ovarian Cancer Screening
Study. <i> J Clin Oncol</i>. 2017;35(13):1411-1420.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28240969" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Evidence%20of%20stage%20shift%20in%20women%20diagnosed%20with%20ovarian%20cancer%20during%20phase%20II%20of%20the%20UK%20Familial%20Ovarian%20Cancer%20Screening%20Study.&author=AN%20Rosenthal&author=LSM%20Fraser&author=S%20Philpott&publication_year=2017&journal=J%20Clin%20Oncol&volume=35&pages=1411-1420" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1200/JCO.2016.69.9330" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r10">10.</a><br />
<div class="reference-content">
Skates
SJ, Greene
MH, Buys
SS,
et al. Early detection of ovarian cancer using the Risk of Ovarian
Cancer Algorithm with frequent CA125 testing in women at increased
familial risk. <i> Clin Cancer Res</i>. 2017;23(14):3628-3637.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28143870" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Early%20detection%20of%20ovarian%20cancer%20using%20the%20Risk%20of%20Ovarian%20Cancer%20Algorithm%20with%20frequent%20CA125%20testing%20in%20women%20at%20increased%20familial%20risk.&author=SJ%20Skates&author=MH%20Greene&author=SS%20Buys&publication_year=2017&journal=Clin%20Cancer%20Res&volume=23&pages=3628-3637" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1158/1078-0432.CCR-15-2750" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r11">11.</a><br />
<div class="reference-content">
Karlan
BY, Thorpe
J, Watabayashi
K,
et al. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. <i> Cancer Epidemiol Biomarkers Prev</i>. 2014;23(7):1383-1393.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/24789859" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Use%20of%20CA125%20and%20HE4%20serum%20markers%20to%20predict%20ovarian%20cancer%20in%20elevated-risk%20women.&author=BY%20Karlan&author=J%20Thorpe&author=K%20Watabayashi&publication_year=2014&journal=Cancer%20Epidemiol%20Biomarkers%20Prev&volume=23&pages=1383-1393" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1158/1055-9965.EPI-13-1361" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r12">12.</a><br />
<div class="reference-content">
Menon
U, McGuire
AJ, Raikou
M,
et al. The cost-effectiveness of screening for ovarian cancer:
results from the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS). <i> Br J Cancer</i>. 2017;117(5):619-627.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28742794" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20cost-effectiveness%20of%20screening%20for%20ovarian%20cancer%3A%20results%20from%20the%20UK%20Collaborative%20Trial%20of%20Ovarian%20Cancer%20Screening%20(UKCTOCS).&author=U%20Menon&author=AJ%20McGuire&author=M%20Raikou&publication_year=2017&journal=Br%20J%20Cancer&volume=117&pages=619-627" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1038/bjc.2017.222" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r13">13.</a><br />
<div class="reference-content">
Sieh
W, Salvador
S, McGuire
V,
et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian
Cancer Study Group; Ovarian Cancer Association Consortium. Tubal
ligation and risk of ovarian cancer subtypes. <i> Int J Epidemiol</i>. 2013;42(2):579-589.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/23569193" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Tubal%20ligation%20and%20risk%20of%20ovarian%20cancer%20subtypes.&author=W%20Sieh&author=S%20Salvador&author=V%20McGuire&publication_year=2013&journal=Int%20J%20Epidemiol&volume=42&pages=579-589" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1093/ije/dyt042" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r14">14.</a><br />
<div class="reference-content">
Garcia
C, Martin
M, Tucker
LY,
et al. Experience with opportunistic salpingectomy in a large, community-based health system in the United States. <i> Obstet Gynecol</i>. 2016;128(2):277-283.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/27399999" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Experience%20with%20opportunistic%20salpingectomy%20in%20a%20large%2C%20community-based%20health%20system%20in%20the%20United%20States.&author=C%20Garcia&author=M%20Martin&author=LY%20Tucker&publication_year=2016&journal=Obstet%20Gynecol&volume=128&pages=277-283" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1097/AOG.0000000000001531" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r15">15.</a><br />
<div class="reference-content">
Powell
CB, Swisher
EM, Cass
I,
et al. Long-term follow-up of BRCA1 and BRCA2 mutation carriers
with unsuspected neoplasia identified at risk reducing
salpingo-oophorectomy. <i> Gynecol Oncol</i>. 2013;129(2):364-371.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/23391663" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Long-term%20follow-up%20of%20BRCA1%20and%20BRCA2%20mutation%20carriers%20with%20unsuspected%20neoplasia%20identified%20at%20risk%20reducing%20salpingo-oophorectomy.&author=CB%20Powell&author=EM%20Swisher&author=I%20Cass&publication_year=2013&journal=Gynecol%20Oncol&volume=129&pages=364-371" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1016/j.ygyno.2013.01.029" target="_blank">Crossref</a></div>
</div>
<div class="reference">
<a class="reference-number" href="https://www.blogger.com/null" id="ced180001r16">16.</a><br />
<div class="reference-content">
Labidi-Galy
SI, Papp
E, Hallberg
D,
et al. High grade serous ovarian carcinomas originate in the fallopian tube. <i> Nat Commun</i>. 2017;8(1):1093.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29061967" target="_blank">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=High%20grade%20serous%20ovarian%20carcinomas%20originate%20in%20the%20fallopian%20tube.&author=SI%20Labidi-Galy&author=E%20Papp&author=D%20Hallberg&publication_year=2017&journal=Nat%20Commun&volume=8&pages=1093" target="_blank">Google Scholar</a><a class="crossref-doi" href="https://doi.org/10.1038/s41467-017-00962-1" target="_blank">Crossref</a></div>
</div>
</div>
<div class="sidebar">
<br />
<div class="widget-PersonalizedContent widget-instance-AMA_PersonalizedContent_MagazineView_RightRail loaded">
<h4 class="ymal--hed thm-col-sec">
You May Also Like
</h4>
<ul class="ymal--content featured-list--contents">
<li class="article ymal--item">
<div class="article--type black fw-b text-normal fs-n d-ib va-m">
Research
</div>
<a class="article--title fw-n d-b lh-text" href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2665173?widget=personalizedcontent&previousarticle=2672788">
Estimating Cost-effectiveness of a Multimodal
Ovarian Cancer Screening Program in the United States: Secondary
Analysis of the UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS)
</a>
<div class="article--date meta-item no-wrap">
February 1, 2018</div>
</li>
<li class="article ymal--item">
<div class="article--type black fw-b text-normal fs-n d-ib va-m">
Research
</div>
<a class="article--title fw-n d-b lh-text" href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2669778?widget=personalizedcontent&previousarticle=2672788">
Use of Single-Nucleotide Polymorphisms and
Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk
Prediction
</a>
<div class="article--date meta-item no-wrap">
January 18, 2018</div>
</li>
<li class="article ymal--item">
<div class="article--type black fw-b text-normal fs-n d-ib va-m">
Opinion
</div>
<a class="article--title fw-n d-b lh-text" href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2536198?widget=personalizedcontent&previousarticle=2672788">
Routine Cancer Antigen 125 Surveillance—The Fatal Attraction of Testing
</a>
<div class="article--date meta-item no-wrap">
November 1, 2016</div>
</li>
</ul>
</div>
</div>
<div class="ymal--footer">
<div class="widget-PersonalizedContent widget-instance-AMA_PersonalizedContent_MagazineView_Footer loaded">
<div class="row ymal">
<h4 class="ymal--hed thm-col-sec">
You May Also Like
</h4>
<ul class="ymal--content featured-list--contents">
<li class="article ymal--item thm-bd-top bd-jama-sec">
<a class="article--title d-b mb05" href="https://jamanetwork.com/journals/jama/fullarticle/2672637?widget=personalizedcontent&previousarticle=2672788">Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force</a>
<div class="article--pub-name meta-item">
JAMA</div>
<div class="article--type meta-item">
Research</div>
<div class="article--date meta-item no-wrap">
February 13, 2018</div>
</li>
<li class="article ymal--item thm-bd-top bd-jama-sec">
<a class="article--title d-b mb05" href="https://jamanetwork.com/journals/jama/fullarticle/2672638?widget=personalizedcontent&previousarticle=2672788">Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement</a>
<div class="article--pub-name meta-item">
JAMA</div>
<div class="article--type meta-item">
Research</div>
<div class="article--date meta-item no-wrap">
February 13, 2018</div>
</li>
<li class="article ymal--item thm-bd-top bd-jama-oncology-sec">
<a class="article--title d-b mb05" href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2665173?widget=personalizedcontent&previousarticle=2672788">Estimating
Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in
the United States: Secondary Analysis of the UK Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS)</a>
<div class="article--pub-name meta-item">
JAMA Oncology</div>
<div class="article--type meta-item">
Research</div>
<div class="article--date meta-item no-wrap">
February 1, 2018</div>
</li>
</ul>
</div>
</div>
</div>
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-3184725317973362632017-01-27T11:03:00.001-05:002017-01-27T11:03:37.526-05:00Cancer Network(2) Lynch Syndrome Associated Ovarian Cancer/Endometrioid/Serous Carcinoma<a href="http://view.email.cmpmedica-usa.com/?qs=272e82ba2b86af205887f593d0cea9166f1b4c4e90b0f15d8eef5a99adcd2e2ee9546af5a8660e1a6e5574ca242036b1a1d1a252018ed1ec112b4cc1cef3f3b9b0c037d3954d8bf4">Cancer Network</a><br />
<br />
<a href="http://click.email.cmpmedica-usa.com/?qs=dde674bbb80740bfa2e97ca9e78a6ee2bb9a80595563e89f25675441d553b1e9" style="color: #323232; font-family: Arial; font-size: 20px; text-decoration: none;" target="_blank">OVARIAN CANCER</a>
<br />
<table border="0" cellpadding="0" cellspacing="0" class="100p">
<tbody>
<tr>
<td valign="top">
<table cellpadding="0" cellspacing="0" class="pad10">
<tbody>
<tr>
<td style="font-family: Calibri, 'Gill Sans MT', 'Myriad Pro', 'DejaVu Sans Condensed', Helvetica, Arial, sans-serif; font-size: 16px; font-style: normal; font-weight: bold; letter-spacing: normal; line-height: 100%; margin-bottom: 0; margin-left: 0; margin-right: 0; margin-top: 0; padding: 3px; text-align: left;">
<a href="http://click.email.cmpmedica-usa.com/?qs=dde674bbb80740bfa2e97ca9e78a6ee2bb9a80595563e89f25675441d553b1e9" style="color: #217c8c; font-family: Arial; font-size: 19px; text-decoration: none;" target="_blank"><u>Lynch Syndrome-Associated Ovarian Cancer Presents Early, Has Good Prognosis</u></a>
</td>
</tr>
<tr>
<td style="color: #555555; font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px; padding: 3px 10px 3px 3px; text-align: left;" valign="top">
An analysis of Lynch syndrome-associated
ovarian cancer found that the malignancy tends to present at an early
stage and has a generally good prognosis. <a href="http://click.email.cmpmedica-usa.com/?qs=dde674bbb80740bfa2e97ca9e78a6ee2bb9a80595563e89f25675441d553b1e9" style="color: #217c8c; font-weight: bold; line-height: 100%; text-decoration: none;" target="_blank"> Read More »</a>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<table border="0" cellpadding="0" cellspacing="0" class="pad10"><tbody>
<tr>
<td style="font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px; font-style: normal; font-weight: bold; letter-spacing: normal; line-height: 100%; margin-bottom: 0; margin-left: 0; margin-right: 0; margin-top: 0; padding: 30px 10px 3px 3px; text-align: left;">
<a href="http://click.email.cmpmedica-usa.com/?qs=dde674bbb80740bfa2e97ca9e78a6ee2bb9a80595563e89f25675441d553b1e9" style="color: #217c8c; font-family: Arial; font-size: 19px; text-decoration: none;" target="_blank"><u>Endometrioid Ovarian Cancer Presents Earlier, Offers Better Survival Than Serous Carcinoma</u></a>
</td>
</tr>
<tr>
<td style="color: #555555; font-family: Calibri, Arial, Helvetica, sans-serif; font-size: 16px; padding: 3px 10px 3px 3px; text-align: left;" valign="top">
Women with endometrioid ovarian cancer present at a
younger age and with earlier stage disease than those with serous
ovarian cancer, according to a new analysis. The earlier presentation
resulted in better 5- and 10-year overall survival rates as well. <a href="http://click.email.cmpmedica-usa.com/?qs=dde674bbb80740bfa2e97ca9e78a6ee2bb9a80595563e89f25675441d553b1e9" style="color: #217c8c; font-weight: bold; line-height: 100%; text-decoration: none;" target="_blank">Read More »</a></td></tr>
</tbody></table>
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-20529754798011658602017-01-27T11:01:00.001-05:002017-01-27T11:01:08.412-05:00Feb 6th Webinar: Looking Ahead: Ovarian Cancer Advocacy in 2017<a href="http://campaign.r20.constantcontact.com/render?m=1102150261756">Looking Ahead: Ovarian Cancer Advocacy in 2017</a><br />
<br />
<br />
<div align="center" style="text-align: center;">
Webinar </div>
<div align="center" style="text-align: center;">
Ovarian Cancer Advocacy Update: What You Need to Know</div>
<div align="center" style="text-align: center;">
<span style="background-color: #ffe599;">Monday, February 6 at 6pm Eastern (Webinar is Free)</span></div>
<div align="center" style="text-align: center;">
<div>
With a new Congress and a new President, where do we stand with issues that impact the ovarian cancer community? </div>
<br /><div>
Join OCRFA's Vice President of Policy, Chad Ramsey, for an important <a alt="https://ocrf.webex.com/mw3100/mywebex/default.do?siteurl=ocrf" href="http://r20.rs6.net/tn.jsp?f=001XZS_XgjOB6RSDDzobe1Rwsx-Hk05RLYehbYzNhHo5Q3dZEyuy8NDMyUNeh9GUfIREpRfCX48w2qMvIjN_AA-8Q5YZSCqdEsz5VrBEOsYNidTuESZgquz0kmaXK6WoM9l_wQqqZJlWEk5qWCDagd42ga5hBtFGMYz5bhoWEBHJChFAvqC_cVZuzurToMupeXbD9FGW1RJPLC865PfCvCYAUYm9CMQqcOy76bLbXlX65g=&c=&ch=" shape="rect" style="color: blue; text-decoration: underline;" target="_blank">policy update webinar</a> with a Q&A afterwards. </div>
<br /><div>
Chad
will be updating us about potential changes to healthcare policy, the
status of biomedical research, and OCRFA's proactive policy agenda for
2017. </div>
<br />You won't want to miss this. Can't make the live
presentation? Sign up - all registrants will receive a link to the
recorded presentation when it's available.<span> </span></div>
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-53216820234048186662017-01-27T09:28:00.001-05:002017-01-27T09:28:44.856-05:00Newly released 2017 Canadian Nonprofit Sector Salary & Benefits Report reveals current compensation trends<a href="https://charityvillage.com/Content.aspx?topic=Newly_released_2017_Canadian_Nonprofit_Sector_Salary_Benefits_Report_reveals_current_compensation_trends">Newly released 2017 Canadian Nonprofit Sector Salary & Benefits Report reveals current compensation trends</a><br />
<br />
<blockquote class="tr_bq">
<h3>
Cash compensation continues to grow slowly for many</h3>
Average cash compensation increased in the nonprofit sector, except
for front-line and support staff, between 2013 and 2016. When increases
were received, the majority were less than 3%. The most significant
increase was among management/supervisory staff at a cumulative 15%
since 2013. This growth will need to be monitored to determine if it is a
trend or a temporary spike.</blockquote>
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-21889080022521932132017-01-27T09:13:00.001-05:002017-01-27T09:13:45.112-05:00OA: Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery...<a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2816%2931596-3/fulltext?elsca1=etoc">Mesh, graft, or standard repair for women having primary transvaginal anterior or posterior compartment prolapse surgery: two parallel-group, multicentre, randomised, controlled trials (PROSPECT) - The Lancet</a><br />
<br />
<h3 class="sectionTitle">
Interpretation</h3>
Augmentation of a vaginal
repair with mesh or graft material<span style="background-color: #ffe599;"> did not improve women's outcomes in
terms of effectiveness, quality of life, adverse effects, or any other
outcome in the short term</span>, but <span style="background-color: #ffe599;">more than one in ten women had a mesh
complication. </span>Therefore, follow-up is vital to identify any longer-term
potential benefits and serious adverse effects of mesh or graft
reinforcement in vaginal prolapse surgery.<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-79423808051628476412017-01-27T08:37:00.001-05:002017-01-27T08:37:05.292-05:00Familial Cancer journal January Index (not an OA publication)<a href="http://link.springer.com/journal/10689/16/1?wt_mc=alerts.TOCjournals">Familial Cancer</a><br />
<br />
<br />
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-47465476589745808492017-01-27T08:26:00.001-05:002017-01-27T08:26:58.154-05:00(Seromucinous) Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary<a href="https://www.ncbi.nlm.nih.gov/pubmed/28125452">abstract</a><br />
<i>Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary</i><br />
<br />
<div class="abstr">
<div class="">
<span style="background-color: #ffe599;">The
2014 World Health Organization Classification of Tumors of Female
Reproductive Organs endorsed the new category of seromucinous carcinoma,
a neoplasm that exhibits morphologic and immunophenotypic overlap with
other histotypes of ovarian carcinoma.</span> The goal of this study was to
determine whether seromucinous carcinoma was a distinct histotype by
assessing its diagnostic reproducibility and comparing its molecular
composition to the 5 major histotypes of ovarian carcinoma. Thirty-two
tumors diagnosed as seromucinous carcinomas from 2 centers were studied.
Eighteen cases were randomly selected for a review set comprising a
total of 50 ovarian carcinomas of various histotypes. Morphologic
histotype was independently assessed by 4 pathologists. For the 32
seromucinous carcinomas, a histotype-specific immunophenotype was
assigned using a diagnostic immunohistochemical panel.
Histotype-specific genotype was assigned using a combination of
immunohistochemistry and targeted next-generation sequencing for somatic
mutations, including genes recurrently mutated in ovarian carcinomas.
There was low to modest agreement between pathologists with the
reference diagnosis of seromucinous carcinoma, ranging from 39% to 56%
for the 4 observers. The immunophenotype was not unique but overlapped
predominantly with endometrioid and to a lesser extent with mucinous and
low-grade serous carcinoma. Genomic and immunohistochemical alterations
were detected in a number of target genes, including KRAS (70%), PIK3CA
(37%), PTEN (19%), and ARID1A (16%); no CTNNB1 mutations were
identified. Nine cases (30%) harbored concurrent KRAS/PIK3CA mutations.
An endometrioid genotype was assigned to 19 cases, a low-grade serous
genotype to 9, and a mucinous genotype to 1 and 3 cases were
uninformative. Integrating morphology, immunophenotype, and genotyping
resulted in reclassifying the seromucinous carcinomas to endometrioid
23/32 (72%), low-grade serous 8/32 (25%), and mucinous 1/32 (3%). <span style="background-color: #ffe599;">The
morphologic diagnosis of seromucinous carcinomas is not very reliable
and it does not exhibit a distinct immunophenotype or genotype. </span>The
molecular features overlap mostly with endometrioid and low-grade serous
carcinomas. <span style="background-color: #ffe599;">Our data suggest the category of seromucinous carcinoma be
discontinued</span> as ancillary molecular tests can assign cases to one of the
major histotypes.</div>
</div>
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-43180274113929805922017-01-26T20:49:00.001-05:002017-01-26T20:49:17.009-05:00Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment<a href="http://cancerres.aacrjournals.org/content/early/2017/01/26/0008-5472.CAN-16-2490">abstract AACR Cancer Research</a><br />
<br />
With the recent advent of immunotherapy, there is a critical need to
understand immune cell interactions in the tumor microenvironment in
both pan-cancer and tissue-specific contexts. Multi-dimensional datasets
have enabled systematic approaches to dissect these interactions in
large numbers of patients, <span style="background-color: #ffe599;">furthering our understanding of the patient
immune response to solid tumors</span>. Using an integrated approach, we
infered the infiltration levels of distinct immune cell subsets in <span style="background-color: #ffe599;">23
tumor types from The Cancer Genome Atlas</span>. From these quantities, we
constructed a co-infiltration network, revealing interactions between
cytolytic cells and myeloid cells in the tumor microenvironment. By
integrating patient mutation data, <span style="background-color: #ffe599;">we show that while mutation burden
was associated with immune infiltration differences between distinct
tumor types, additional factors may explain immunogenic differences
between tumors originating from the same tissue.</span> Finally, we examined
the prognostic value of individual immune cell subsets as well as how
co-infiltration of functionally discordant cell types associated with
patient survival. We showed in multiple tumor types that the <span style="background-color: #ffe599;">protective
effect of CD8+ T cell</span> infiltration was heavily modulated by
co-infiltration of macrophages and other myeloid cell types, suggesting
the involvement of myeloid-derived suppressor cells in tumor
development. Our findings illustrate complex interactions between
different immune cell types in the<span style="background-color: #ffe599;"> tumor microenvironment and indicate
these interactions play meaningful roles in patient survival.</span> These
results demonstrate the importance of personalized immune response
profiles when studying the factors underlying tumor immunogenicity and
immunotherapy response.<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-45376021033927049822017-01-26T20:32:00.001-05:002017-01-26T20:32:37.553-05:00SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers - The ASCO Post <strong> </strong><img alt="Surveillance, Epidemiology, and End Results Program" height="27" src="https://seer.cancer.gov/i/seer.svg" width="320" /><br />
<br />
<strong><a href="https://seer.cancer.gov/statfacts/html/ovary.html" target="_blank">Number of New Cases and Deaths per 100,000</a>:</strong> The number
of new cases of ovarian cancer was 11.9 per 100,000 women per year. The
number of deaths was 7.5 per 100,000 women per year. These rates are
age-adjusted and based on 2009-2013 cases and deaths.<br />
<strong>Lifetime Risk of Developing Cancer</strong>: Approximately 1.3
percent of women will be diagnosed with ovarian cancer at some point
during their lifetime, based on 2011-2013 data.<span class="st"></span><br />
~~~~~~~~~~~~~~~~~~<br />
<a href="http://www.ascopost.com/News/48300">The ASCO Post</a><br />
<div class="article-byline">
<br />
<i>Posted: 1/26/2017</i> <span data-inline-tweet-title="SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers " data-inline-tweet-via="ascopost" data-inline-tweet=""><svg style="height: 0.7em;" viewbox="0 0 182.66667 150.66667" xml:space="preserve" xmlns="http://www.w3.org/2000/svg"><defs id="defs6"></defs><g id="g10" transform="matrix(1.3333 0 0 -1.3333 0 150.67)"><g id="g12" transform="scale(.1)"><g id="g14"><g clip-path="url(#clipPath20)" id="g16"></g></g></g></g></svg></span></div>
<div class="article-byline">
<span data-inline-tweet-title="SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers " data-inline-tweet-via="ascopost" data-inline-tweet=""><svg style="height: 0.7em;" viewbox="0 0 182.66667 150.66667" xml:space="preserve" xmlns="http://www.w3.org/2000/svg"><g id="g10" transform="matrix(1.3333 0 0 -1.3333 0 150.67)"><g id="g12" transform="scale(.1)"></g></g></svg></span> </div>
<div class="article-byline">
People with rare cancers now have the option of joining a national
clinical trial testing leading-edge immunotherapies for a wide variety
of tumor types. <span style="background-color: #ffe599;">It’s the first federally funded immunotherapy trial
devoted to rare cancers</span>. Despite their name, rare cancers make up more
than 20% of cancers diagnosed worldwide.
</div>
The trial is called DART (Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors) and is managed by <a href="http://www.swog.org/" target="_blank">SWOG</a>, the cancer clinical trials group that is part of the <a href="https://www.cancer.gov/" target="_blank">National Cancer Institute’s</a> (NCI) <a href="https://www.cancer.gov/research/areas/clinical-trials/nctn" target="_blank">National Clinical Trials Network</a> (NCTN). The trial is sponsored by the NCI and being conducted under the NCI collaborative agreements with <a href="http://www.bms.com/pages/default.aspx" target="_blank">Bristol-Myers Squibb</a> for ipilimumab (Yervoy) and nivolumab (Opdivo).<br />
<br />
<strong>DART and NCI-MATCH</strong><br />
The trial draws on the design and takes advantage of the scale of another landmark trial offered through the NCTN, <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match" target="_blank">NCI-MATCH</a>
(NCI-Molecular Analysis for Therapy Choice), a precision medicine trial
open at more than 1,000 clinical sites. Codesigned by the <a href="http://ecog-acrin.org/" target="_blank">ECOG-ACRIN</a>
Cancer Research Group and the NCI, and led by ECOG-ACRIN, NCI-MATCH is
the most sweeping precision medicine trial in the United States.
NCI-MATCH uses a customized tumor gene testing method to match patients
with any solid tumor, along with lymphoma and myeloma, to multiple
targeted treatments. Currently, there are 24 treatments offered, with
plans to add about 10 more. Since NCI-MATCH was launched in August 2015,
more than 2,500 patients have completed tumor gene testing out of the
6,000 patients intended to be screened. As of December 1, 2016, nearly
300 patients have entered treatment arms.<br />
According to the definition used for the DART trial, <span style="background-color: #ffe599;">rare cancers are
those diseases with less than a 6 in 100,000 incidences per year</span>. These
include dozens of types, including cancers in nerves, glands, bones,
and skin. But only certain patients will be eligible to enroll in DART.
To join, patients must be registered to NCI-MATCH. If they don’t have a
treatment option under NCI-MATCH, or if they didn’t respond to treatment
on that trial, and their rare cancer is eligible, they can enroll......<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0tag:blogger.com,1999:blog-9029913.post-11892812088886269552017-01-26T16:13:00.003-05:002017-01-26T16:13:38.664-05:00cute and happy pics in tweetoff: #cuteanimaltweetoff<h1 class="AdaptiveSearchTitle-title" dir="ltr">
<span style="font-size: small;"><a href="https://twitter.com/hashtag/cuteanimaltweetoff?f=tweets&vertical=news&src=hash" target="_blank">#cuteanimaltweetoff</a></span></h1>
<div class="blogger-post-footer">Comments?
</div>OvarianCancerandUshttp://www.blogger.com/profile/16341582595104380399noreply@blogger.com0